Marina
Blanco Aparicio
Corporació Sanitària Parc Taulí
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (6)
2023
-
Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
Frontiers in Pharmacology, Vol. 14
-
Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain
Open Respiratory Archives, Vol. 5, Núm. 3
2022
-
Consensus document for severe asthma in adults. 2022 update
Open Respiratory Archives, Vol. 4, Núm. 3
-
Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map
Journal of Asthma, Vol. 59, Núm. 10, pp. 1997-2007
2021
-
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)
Drugs
-
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
Drugs, Vol. 81, Núm. 15, pp. 1763-1774